CPC A61K 31/215 (2013.01) [A61P 25/24 (2018.01)] | 17 Claims |
1. A method for the treatment or reducing the risk of a retinoid X receptor (RXR)-mediated signaling dysfunction by providing (R)-9-cis-13,14-dihydroretinoic acid (9CDHRA) as an RXR ligand in a subject, said method selected from the group consisting of
ameliorating or reducing the development of, ameliorating at least one physical parameter of, or inhibiting cancer or depression,
ameliorating or reducing the risk of vitamin A5 deficiency, and
ameliorating or reducing memory impairment,
said method comprising administration of a compound of general formula (I) to a mammalian subject suffering from or being endangered by a retinoid X receptor-mediated signaling dysfunction in the nervous system,
wherein
R is a group of general formula (A)
wherein Q1 is an unsubstituted trimethylcyclohexenyl group so that the compound of general formula (I) is 9-cis-13,14-dihydro-β,β-carotene or a 9-cis-13,14-dihydro-β,α-carotene, or
R is —CH2OR2, wherein R2 is H or an acyl group —C(O)R3 wherein —C(O)R3 is a group which is removed by hydrolysis in a mammalian tissue or organ to result in (R)-9-cis-13,14-dihydroretinol and a biologically acceptable tolerable compound, wherein R3 is a C1-25 alkyl or a C2-25 alkenyl, or
R is —COOH,
said compound of general formula (I) being converted into (R)-9-cis-13,14-dihydroretinoic acid in a tissue or organ or cells of the mammalian subject.
|